Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 51 studies | 58% ± 19% | |
capillary endothelial cell | 18 studies | 52% ± 18% | |
endothelial cell of artery | 15 studies | 49% ± 15% | |
vein endothelial cell | 14 studies | 47% ± 14% | |
endothelial cell of vascular tree | 13 studies | 47% ± 19% | |
pericyte | 9 studies | 56% ± 28% | |
Mueller cell | 6 studies | 63% ± 11% | |
endothelial cell of sinusoid | 4 studies | 55% ± 22% | |
glomerular endothelial cell | 4 studies | 85% ± 2% | |
extravillous trophoblast | 3 studies | 83% ± 6% | |
placental villous trophoblast | 3 studies | 44% ± 19% | |
OFF-bipolar cell | 3 studies | 23% ± 6% | |
astrocyte | 3 studies | 33% ± 9% | |
fibroblast | 3 studies | 54% ± 16% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
placenta | 3 studies | 59% ± 14% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
breast | 100% | 10552.11 | 459 / 459 | 95% | 15.18 | 1063 / 1118 |
brain | 98% | 4903.93 | 2583 / 2642 | 97% | 13.83 | 682 / 705 |
lung | 100% | 8626.34 | 577 / 578 | 94% | 13.13 | 1081 / 1155 |
thymus | 100% | 17608.92 | 653 / 653 | 91% | 36.06 | 553 / 605 |
kidney | 100% | 9342.85 | 89 / 89 | 83% | 96.20 | 748 / 901 |
bladder | 100% | 3472.95 | 21 / 21 | 81% | 9.17 | 409 / 504 |
prostate | 98% | 5031.23 | 240 / 245 | 83% | 11.39 | 417 / 502 |
adrenal gland | 86% | 2739.64 | 221 / 258 | 93% | 26.01 | 214 / 230 |
stomach | 91% | 2475.18 | 327 / 359 | 87% | 10.71 | 250 / 286 |
uterus | 99% | 6178.39 | 168 / 170 | 71% | 7.84 | 328 / 459 |
esophagus | 80% | 2693.31 | 1150 / 1445 | 90% | 12.71 | 165 / 183 |
intestine | 90% | 3155.96 | 872 / 966 | 77% | 8.84 | 405 / 527 |
pancreas | 60% | 1187.65 | 196 / 328 | 97% | 16.42 | 173 / 178 |
skin | 57% | 1354.22 | 1030 / 1809 | 72% | 8.28 | 341 / 472 |
liver | 37% | 1138.05 | 84 / 226 | 77% | 7.91 | 313 / 406 |
adipose | 100% | 13846.52 | 1204 / 1204 | 0% | 0 | 0 / 0 |
heart | 100% | 7992.80 | 859 / 861 | 0% | 0 | 0 / 0 |
spleen | 99% | 3060.91 | 239 / 241 | 0% | 0 | 0 / 0 |
muscle | 98% | 3520.06 | 783 / 803 | 0% | 0 | 0 / 0 |
ovary | 45% | 1096.61 | 81 / 180 | 41% | 2.64 | 177 / 430 |
blood vessel | 75% | 2784.36 | 1005 / 1335 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 69% | 7.53 | 31 / 45 |
lymph node | 0% | 0 | 0 / 0 | 38% | 2.95 | 11 / 29 |
eye | 0% | 0 | 0 / 0 | 13% | 1.11 | 10 / 80 |
peripheral blood | 8% | 233.63 | 76 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0001525 | Biological process | angiogenesis |
GO_0007169 | Biological process | cell surface receptor protein tyrosine kinase signaling pathway |
GO_0045766 | Biological process | positive regulation of angiogenesis |
GO_1905563 | Biological process | negative regulation of vascular endothelial cell proliferation |
GO_0007275 | Biological process | multicellular organism development |
GO_0043410 | Biological process | positive regulation of MAPK cascade |
GO_0038084 | Biological process | vascular endothelial growth factor signaling pathway |
GO_0043406 | Biological process | positive regulation of MAP kinase activity |
GO_0033674 | Biological process | positive regulation of kinase activity |
GO_0018108 | Biological process | peptidyl-tyrosine phosphorylation |
GO_0048598 | Biological process | embryonic morphogenesis |
GO_0030335 | Biological process | positive regulation of cell migration |
GO_0030154 | Biological process | cell differentiation |
GO_0036323 | Biological process | vascular endothelial growth factor receptor-1 signaling pathway |
GO_0048010 | Biological process | vascular endothelial growth factor receptor signaling pathway |
GO_0008284 | Biological process | positive regulation of cell population proliferation |
GO_0051897 | Biological process | positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction |
GO_0048514 | Biological process | blood vessel morphogenesis |
GO_0002548 | Biological process | monocyte chemotaxis |
GO_0046777 | Biological process | protein autophosphorylation |
GO_0035924 | Biological process | cellular response to vascular endothelial growth factor stimulus |
GO_0016477 | Biological process | cell migration |
GO_1990384 | Biological process | hyaloid vascular plexus regression |
GO_0005615 | Cellular component | extracellular space |
GO_0043235 | Cellular component | receptor complex |
GO_0005886 | Cellular component | plasma membrane |
GO_0005925 | Cellular component | focal adhesion |
GO_0015629 | Cellular component | actin cytoskeleton |
GO_0005768 | Cellular component | endosome |
GO_0005021 | Molecular function | vascular endothelial growth factor receptor activity |
GO_0036332 | Molecular function | placental growth factor receptor activity |
GO_0004714 | Molecular function | transmembrane receptor protein tyrosine kinase activity |
GO_0019838 | Molecular function | growth factor binding |
GO_0005524 | Molecular function | ATP binding |
GO_0005515 | Molecular function | protein binding |
Gene name | FLT1 |
Protein name | Soluble FLT1 variant e15a p19FLT1 Platelet-derived growth factor receptor-like protein Vascular endothelial growth factor receptor 1 (VEGFR-1) (EC 2.7.10.1) (Fms-like tyrosine kinase 1) (FLT-1) (Tyrosine-protein kinase FRT) (Tyrosine-protein kinase receptor FLT) (FLT) (Vascular permeability factor receptor) Vascular endothelial growth factor receptor 1 variant receptor protein-tyrosine kinase (EC 2.7.10.1) p28FLT1 Vascular endothelial growth factor receptor 1 (EC 2.7.10.1) |
Synonyms | VEGFR1 FRT FLT |
Description | FUNCTION: Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFB and PGF, and plays an essential role in the development of embryonic vasculature, the regulation of angiogenesis, cell survival, cell migration, macrophage function, chemotaxis, and cancer cell invasion. Acts as a positive regulator of postnatal retinal hyaloid vessel regression (By similarity). May play an essential role as a negative regulator of embryonic angiogenesis by inhibiting excessive proliferation of endothelial cells. Can promote endothelial cell proliferation, survival and angiogenesis in adulthood. Its function in promoting cell proliferation seems to be cell-type specific. Promotes PGF-mediated proliferation of endothelial cells, proliferation of some types of cancer cells, but does not promote proliferation of normal fibroblasts (in vitro). Has very high affinity for VEGFA and relatively low protein kinase activity; may function as a negative regulator of VEGFA signaling by limiting the amount of free VEGFA and preventing its binding to KDR. Modulates KDR signaling by forming heterodimers with KDR. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate and the activation of protein kinase C. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, leading to activation of phosphatidylinositol kinase and the downstream signaling pathway. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Phosphorylates SRC and YES1, and may also phosphorylate CBL. Promotes phosphorylation of AKT1 at 'Ser-473'. Promotes phosphorylation of PTK2/FAK1 . .; FUNCTION: [Isoform 1]: Phosphorylates PLCG. .; FUNCTION: [Isoform 2]: May function as decoy receptor for VEGFA. .; FUNCTION: [Isoform 3]: May function as decoy receptor for VEGFA. .; FUNCTION: [Isoform 4]: May function as decoy receptor for VEGFA. .; FUNCTION: [Isoform 7]: Has a truncated kinase domain; it increases phosphorylation of SRC at 'Tyr-418' by unknown means and promotes tumor cell invasion. . |
Accessions | A0A1W2PNW4 V9Q458 X2QEJ0 ENST00000639477.1 X2CBY1 ENST00000615840.5 [P17948-2] ENST00000282397.9 [P17948-1] V9Q5H8 X2C8T1 P17948 H9N1E8 X2QIK8 ENST00000539099.2 [P17948-4] B1AC84 L7RSL3 H9N1E7 ENST00000541932.5 [P17948-3] |